Atezolizumab - Genentech

Drug Profile

Atezolizumab - Genentech

Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RO-5541267; TECENTRIQ

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer Amgen; ARCAGY/GINECO Group; Astex Pharmaceuticals; BioLineRx; Chugai Pharmaceutical; Clovis Oncology; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Exelixis; Fondazione Michelangelo; Genentech; Gradalis; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; National Cancer Institute (USA); Netherlands Cancer Institute; Roche; University Hospital Southampton NHS Foundation Trust; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Registered Bladder cancer
  • Phase III Breast cancer; Colorectal cancer; Fallopian tube cancer; Hepatocellular carcinoma; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Brain metastases; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Gastric cancer; Gynaecological cancer; Head and neck cancer; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Oesophageal cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Follicular lymphoma; Glioblastoma; Pancreatic cancer
  • Phase I Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 09 Apr 2018 Registration for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in Canada (IV)
  • 09 Apr 2018 Suspended - Phase-II for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in United Kingdom, Portugal, Serbia, Netherlands, Italy, Bosnia-Herzegovina, Denmark, France, South Africa, Slovakia, Spain, Sweden, South Korea, Russia, Poland, Mexico, Germany, Greece, Brazil, Belgium, Egypt, Turkey, Argentina (IV) (NCT02291289)
  • 09 Apr 2018 Adverse events and efficacy data from phase III OAK study in Non-small cell lung cancer released by Hoffmann-La Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top